News Articles for Argent BioPharma

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
Runners of the Week Bulls N' Bears 10 Jan 2025

Sparc fires up following three-way hydrogen tie-in

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

This week's Bulls N' Bears Runner of the Week is … Sparc Technologies. The company is developing new-age hydrogen technology using sunlight to split water without the use of an electrolyser. Argent Biopharma raised funds at a significant premium to its last closing price while Australian Mines boosted its scandium resource and Dimerix revealed a tie-in with a Japanese pharmaceutical firm to treat kidney disease.

Appointments 01 Dec 2023

Board Moves December 1, 2023

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Our board moves wrap includes Dianne Angus, Geoff Pocock, Andrew Chapman, Tod McGrouther, Gaurav Gupta, Mark Licciardo, Joel Ives, Karen Logan, Joan Dabon, Harry Spindler, Dan Robinson, Stephen Parker, Ross Walker, Stephen Carter, Grant Lukey, Rhett Morson, Bruce Rathie, Alec PIsmiris, Geoff Stalley, Kenneth Hall, Cathy Moises, and Brady Hall.

Appointments 07 Jun 2023

Board Moves May 31 to June 2, 2023

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Our board moves wrap includes Stephen Windle, Robert Black, Joanna Kiernan, Erlyn Dawson, Alessandra Gauvin, Brett Tucker, Layton Mills, Brett Mitchell, Nativ Segev, Stephen Parker, Duncan Anderson, Danielle Lee, Matt Adams, Caroline Brokvam, Ian Finch, Donna Gentile O'Donnell, and Lisa Gray.

Appointments 01 Mar 2023

Board Moves March 1, 2023

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Our board moves wrap includes Chris Radin, Sheila Khama, Stirling Ross, Gerry Kaczmarek, Tony Kiernan, Derek Humphry, Dale Richards, Nerida Schmidt, Patricia Farr, Simon Robertson, Susan Park, Peter Webse, ChongTao Xu, Andrew Taplin, Carol Marinkovich, Rowan Harland, Arron Canicais, David Lim, Andrew Woskett, Benjamin Donovan, and Shaun Menezes.

Appointments 15 Jun 2021

Board Moves June 15, 2021

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Our board moves wrap includes James Brown, Gregory Bittar, Adrian Byass, Steve Brockhurst, Nadine Barry, Blair Snowball, Harry Miller, Ashley Lim, Shirley In't Veld, Graeme Smith, Arshad Muhammad, Marcus Goh, Tome Jongue, YiCheng Chen, Eric Kong, Piers Lewis, Victor Goh, Daniel Tydde, and Robert Ierace.

MGC kicks off Perth medicinal cannabis trial Bulls N' Bears 09 Mar 2020

MGC kicks off Perth medicinal cannabis trial

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

ASX-listed MGC Pharmaceuticals has teamed up with the University of Notre Dame in Perth to undertake a new clinical trial for its “CogniCann” phytocannabinoid-derived medicine, after the first bulk shipment of the medicine arrived in Australia. Management said CogniCann was developed with the specific aim to treat symptoms associated with dementia and Alzheimer's disease and it is already available under prescription in Australia.

MGC sets a path for break even with latest medicinal cannabis deal Bulls N' Bears 03 Mar 2020

MGC sets a path for break even with latest medicinal cannabis deal

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Medicinal cannabis player MGC Pharmaceuticals has inked a seven-year supply deal with Brazilian medical cannabis company Onix, with an estimated value of at least $1.65 million in the first year. From year two, the deal, which will see Onix purchase a bulk order of MGC Pharma's pharmaceutical grade products, has an estimated value of at least $4.1 million per year.

MGC Pharma enters Europe with exclusive supply deal in Poland Bulls N' Bears 27 Feb 2020

MGC Pharma enters Europe with exclusive supply deal in Poland

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

ASX-listed MGC Pharma has secured a key market in Europe after signing an exclusive, commercial wholesale supply agreement with Polish NGO, Cannabis House Association and the University of Lodz to supply a large-scale research project in Poland. Under the deal, MGC Pharma will supply its medicinal cannabis-based, cannabinoid medicine products to up to 250 pharmacies and provide scientific support to the commercial research study whilst gathering participant data.

MGC to distribute medical cannabis in South America Bulls N' Bears 28 Jan 2020

MGC to distribute medical cannabis in South America

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has established a distribution agreement to produce and supply its cannabis based medicines to Anden Bio Naturals, giving the ASX listed company access to South American networks containing over 7,500 pharmacies, private clinics and an oncological private insurance system that has over one million listed clients. MGC's pharmaceutical-grade phytocannabinoid products are emerging as an alternative to conventional drugs.

MGC onto new medical cannabis revenue stream Bulls N' Bears 21 Jan 2020

MGC onto new medical cannabis revenue stream

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Medicinal cannabis company, MGC Pharmaceuticals, has inked a new supply agreement that will generate an immediate revenue stream from THC Global Group Limited who will white label MGC's pharmaceutical-grade phytocannabinoid, or “CBD” products to the Australian and New Zealand markets. The products will be sold under THC's “Canndeo” brand and are not expected to compete with MGC's existing cannabis-based product lines.

MGC unveils new “Mercury Pharma” medicinal cannabis brand Bulls N' Bears 07 Jan 2020

MGC unveils new “Mercury Pharma” medicinal cannabis brand

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Medicinal cannabis player, MGC Pharmaceuticals, has unveiled a new medicinal cannabis-based line for Australian and New Zealand markets to be called “Mercury Pharma” with its first product, Mercury Pharma 100, a prescription-only 100mg/mL cannabidiol product. The company has received purchase orders for over 2,000 product units already, which will see revenues of around $270,000 realised.

MGC to receive first batch of cannabis dementia drug Bulls N' Bears 20 Dec 2019

MGC to receive first batch of cannabis dementia drug

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

ASX listed medical cannabis player, MGC Pharmaceuticals, will receive the first bulk shipment of its “CogniCann” product that will see the start of its phase IIb clinical trials to treat dementia and Alzheimer's patients kick off. CogniCann is a GMP certified, pharmaceutical grade, medicinal cannabis product specifically developed for the treatment of dementia symptoms to improve specific cognitive functions.

MGC hits 1800 medicinal cannabis prescriptions Bulls N' Bears 17 Dec 2019

MGC hits 1800 medicinal cannabis prescriptions

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has expanded the number of patients prescribing for or being processed to receive prescriptions for its medical cannabis-based pharmaceutical products in Australia, the UK, Brazil and Ireland with the company racking up over 1800 prescriptions to-date. Management said the milestone readily demonstrates its strengthening position and momentum in those key markets, with its sales graph continuing to climb month by month.

MGC to enter Latin American with medicinal cannabis deal Bulls N' Bears 22 Nov 2019

MGC to enter Latin American with medicinal cannabis deal

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has taken a major step towards capturing the growing Latin American medicinal cannabis market by joining forces with Brazil's leading merchant bank in a ground breaking sales and distribution deal. The joint venture will see MGC and BrasilInvest not only sell and distribute MGC's phytocannabinoid-derived medicines in Brazil, but also in neighbouring countries where the use of medical marijuana has been approved.

MGC lands first Aussie Gov grant Bulls N' Bears 13 Nov 2019

MGC lands first Aussie Gov grant

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has received a Government grant to support its research and development work relating to phyto-cannabinoid derived medicines to treat the symptoms of dementia and Alzheimer's. According to the Australian Bureau of Statistics, dementia is the second leading cause of death for Australians, which means that MGC will have a sizeable addressable market if it's cannabis-based medicinal products can have an impact on this debilitating disease.

MGC writes 1000th medicinal cannabis prescription Bulls N' Bears 31 Oct 2019

MGC writes 1000th medicinal cannabis prescription

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has expanded the number of patients prescribing for or being processed to receive prescriptions of its medical cannabis-based pharmaceutical products in Australia and the UK to around 500 with the company racking up its 1000th prescription this month. Management said that the key milestone readily demonstrates its strengthening position and momentum in those key markets, with its sales graph continuing to climb month by month.

MGC triples medical cannabis patients in a month Bulls N' Bears 17 Oct 2019

MGC triples medical cannabis patients in a month

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has expanded the number of patients prescribing for or being processed to receive prescriptions of its medical cannabis-based pharmaceutical products in both Australia and the UK to beyond 600. The company said that the key milestone readily demonstrates its strengthening position and momentum in those markets to meet the demand for its proprietary standardised, affordable cannabis-based medicines.

MGC grows medical cannabis patient numbers Bulls N' Bears 18 Sep 2019

MGC grows medical cannabis patient numbers

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has expanded the number of patients now prescribing for or being processed to receive prescriptions of its medical cannabis-based pharmaceutical products in Australia and the UK to beyond 200. The company said that the key milestone readily demonstrates its strengthening position in those markets to meet the demand for its proprietary standardised, affordable medicines on a global scale.

MGC lands approval for epilepsy treatment study Bulls N' Bears 03 Sep 2019

MGC lands approval for epilepsy treatment study

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has received Human Research Ethics Committee approval to carry out a clinical study comparing the effectiveness of its medical cannabis products for the treatment of severe epilepsy. This will compare its pharmaceutical-grade low tetrahydrocannabinol medicine authorised for prescription as an Investigational Medicinal Product in Australia and the UK, against its 100% cannabidiol product.

MGC kicks off Slovenian medical cannabis research project Bulls N' Bears 27 Aug 2019

MGC kicks off Slovenian medical cannabis research project

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

ASX-listed MGC Pharmaceuticals has partnered with the Slovenian Institute of Hop Research and Brewing, or “IHPS”, to carry out a ground-breaking, large-scale research project on the use of cannabis for medicinal purposes. The research will focus on the cultivation of cannabis for medical purposes and the standardisation of the process for isolating and extracting an active pharmaceutical ingredient for medicinal use.

MGC to conduct medical cannabis driving trials Bulls N' Bears 23 Aug 2019

MGC to conduct medical cannabis driving trials

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance. The trial seeks to overturn legislation that forbids medical cannabis users from driving and will also provide safety data required for the European Medicines Agency and Australian Therapeutic Goods Administration product registration.

MGC to tap UK markets with London listing Bulls N' Bears 21 Aug 2019

MGC to tap UK markets with London listing

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

Medicinal marijuana player, MGC Pharmaceuticals, is looking to tap into one of Europe's largest public markets through a dual listing on the London Stock Exchange in the second half of the 2019 calendar year. The company will be one of the first medical cannabis companies to list in the UK since legislation was changed in 2018 to allow doctors to prescribe medical cannabis to patients.

MGC builds medical cannabis patient numbers Bulls N' Bears 13 Aug 2019

MGC builds medical cannabis patient numbers

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has added another notch to its belt with 100 patients that have been prescribed or are being processed to receive prescriptions of its medical cannabis-based pharmaceutical products in Australia. The company has also extended its local reach after Tetra Health, who assists medical professionals and patients to obtain safe access to medicinal cannabis products, added MGC's products to their product range.

MGC inks milestone lease for Malta cannabis facility Bulls N' Bears 09 Aug 2019

MGC inks milestone lease for Malta cannabis facility

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals has received the green light to start construction of its large scale, GMP compliant medical cannabis production facility in Malta that will increase its existing production capacity after signing a long-term lease agreement for the 6,000 square metre site. The site works for the facility will commence immediately and the company plans to start construction of the multi-storey building during the current quarter.

MGC targets Chinese nutraceuticals market Bulls N' Bears 07 Aug 2019

MGC targets Chinese nutraceuticals market

Bookmark

Save articles for future reference.
Subscribe to BN Log In
Share to

MGC Pharmaceuticals and Chinese e-commerce marketplace YuShop Global have kicked off a full marketing and sales campaign for MGC's cannabis-based nutraceuticals following a successful eight-week test campaign. Under the distribution agreement between the two companies, YuShop will sell MGC's nutraceutical products to consumers via its online platform and network of retail channel partners, which include 1,500 luxury spas.

X